Investors

Key press releases

06 May 2025
16:30 E.S.T.

Finance

Cellectis to Report First Quarter Financial Results on May 12, 2025

28 Apr 2025
16:30 E.S.T.

Science

Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting

13 Mar 2025
18:15 E.S.T.

Finance

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update

Key upcoming events

13 May 2025 ‐ 17 May 2025

28th American Society of Gene and Cell Therapy Annual Meeting (ASGCT)

05 Jun 2025 ‐ 06 Jun 2025

Jefferies Global Healthcare Conference 2025

09 Jun 2025 ‐ 11 Jun 2025

The Goldman Sachs 46th Annual Global Healthcare Conference

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the Euronext Growth Paris (ticker: ALCLS).

{Currency}{Last}

{Change} ({ChangePercent}%)

Prev. close: {PreviousClose}
Volume: {Volume}
High: {High}
Capitalization: {MarketCap}

See stock information

Covering research analysts

Barclays - Gena Wang

Bryan Garnier - Oscar Haffen-Lamm

Goldman Sachs - Salveen Richter

Jefferies - Kelly Shi

JMP Securities - Silvan Tuerkcan

Jones Trading - Soumit Roy

Kempen - Sebastiaan van der Schoot

Oddo BHF - Martial Descoutures

RW Baird - Jack Allen

Wells Fargo – Yanan Zhu

Cellectis contact information

Arthur Stril, Chief Financial Officer & Chief Business Officer

investors@cellectis.com

Citibank ADR contact information

Intermediaries & Investors
US: +1 212 723 5435
UK: +44 207 500 2030

citiadr@citi.com

Société Générale Securities Services - Ordinary Shares contact information

Call center in English and French

Monday to Friday from 8:30am to 6pm CEST

+33 (0)2 51 85 67 89